Talimogene laherparepvec pseudolymphomatous reaction mimicking metastatic melanoma. (8th July 2021)

• Record Type: Journal Article
• Authors: Henning, Ania; Agnese, Doreen; Chung, Catherine G.
• Is Part Of: Journal of cutaneous pathology. Volume 48:Number 11(2021)
• Page Start: 1423
• Page End: 1426
• Publication Date: 2021-07-08
• Subjects: melanoma -- therapy -- TVEC; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616
• DOI: 10.1111/cup.14094
• Languages: English
• ISSNs: 0303-6987

Abstract

Abstract: Talimogene laherparepvec (TVEC) is a genetically modified herpes simplex virus‐1 approved as an intralesional oncolytic immunotherapy for the treatment of advanced melanoma. Cutaneous reactions at the site of injection may mimic recurrent or progressive melanoma; histopathological findings have included chronic granulomatous dermatitis, neutrophilic dermatitis, lymphocytic dermatitis, and pigment incontinence. We report a 39‐year‐old male with metastatic stage IIIc melanoma treated with TVEC with clinical regression of melanoma lesions that later developed pink nodules at sites of prior injection. Histopathology demonstrated a nodular mononuclear infiltrate that stained strongly and diffusely with CD45 and CD20 with a surrounding rim of CD3‐positive T‐cells. Immunoglobulin gene rearrangement was negative for a clonal B‐cell population. To our knowledge, this is the first report of a pseudolymphomatous reaction mimicking recurrent melanoma after TVEC therapy.